Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Shaoxing Zhu"'
Publikováno v:
Frontiers in Oncology. 12
Bladder cancer (BCa) is a life-threaten disease with an increasing incidence with age, and immunotherapy has become an important treatment for BCa, while the efficiency of the immune system declines with age. It is vital to reveal the mechanisms of t
Publikováno v:
Frontiers in oncology. 12
IntroductionPSMD2 plays an oncogenic role in multiple human malignancies, while it is still unclear that the potential roles and underlying mechanisms of PSMD2 in BCa.MethodsThe RNA-seq from TCGA and GTEx database was utilized to preliminarily analyz
Autor:
Hailong Hu, Jianming Guo, Dahong Zhang, Jian Huang, Lilin Zhang, Ji-Yan Liu, Qing Zou, Aiping Zhou, Xiusong Qiu, Hanzhong Li, Dingwei Ye, Se Hoon Park, Yuanyuan Bao, Jie Jin, Lulin Ma, Cheng Fu, Shaoxing Zhu, F. Bi, Wei Shen, Jun Xiao
Publikováno v:
Cancer Science
Tislelizumab, an anti‐programmed death protein‐1 (PD‐1) monoclonal antibody, was engineered to minimize binding to the FcγR on macrophages to abrogate antibody‐dependent phagocytosis, a mechanism of T‐cell clearance and potential resistanc
Objective Second primary renal cell carcinoma (2nd RCC) refers to renal cell carcinoma (RCC) diagnosed after another unrelated malignancy. This study aims to compare the clinical manifestation, pathology, treatment, and prognostic features of patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a8979f7f8bf41563059a2e53f1d2ba2
https://doi.org/10.21203/rs.3.rs-730176/v2
https://doi.org/10.21203/rs.3.rs-730176/v2
Publikováno v:
Frontiers in Oncology
Frontiers in Oncology, Vol 11 (2021)
Frontiers in Oncology, Vol 11 (2021)
ObjectivesTo evaluate the nature, diagnosis, treatment and prognosis of second primary renal cell carcinoma (SPRCC).Materials and MethodsWe retrospectively collected data from 118 patients with SPRCC. Clinical characteristics, imaging features and tr
Publikováno v:
Frontiers in Oncology, Vol 10 (2021)
Frontiers in Oncology
Frontiers in Oncology
IntroductionIn addition to being rare, metastases to the kidney present clinicians with issues regarding their treatment.Materials and MethodsWe retrospectively analyzed 35 cases of diagnosed renal metastases. The clinical characteristics, imaging fe
Autor:
Yipeng Xu, Shaoxing Zhu, Fangyin Li, Hua Wang, Zongping Wang, Mei Song, Guiping Chen, Yang Zhao
Publikováno v:
Molecular Medicine Reports. 14:3357-3361
Histone methylation, which is regulated by histone methyltransferases (HMTs) and histone demethylases (HDMs), has been indicated to be involved in a variety of diseases, particularly in cancer, including androgen‑independent prostate cancer (PCa).
Publikováno v:
Journal of Clinical Oncology. 38:TPS588-TPS588
TPS588 Background: Platinum-based chemotherapy is standard first-line treatment for patients with advanced urothelial carcinoma (UC). Checkpoint inhibitors (ie, anti-PD-1 antibodies) are first-line treatment options for cisplatin-ineligible patients.
Autor:
Hong Luo, Chaohong He, Chuanjun Du, Xiaojian Qin, Shaoxing Zhu, Zhongquan Sun, Weiqing Han, Qing Zou, Weijie Gu, Tie Chong, Ben Wan, Dingwei Ye, Xin Yao
Publikováno v:
Journal of Clinical Oncology. 38:90-90
90 Background: SHR3680 is a novel and pure androgen-receptor (AR) antagonist that shows a potent antitumor activity against CRPC but with much less brain distribution than enzalutamide in preclinical study. In this first-in-human phase 1/2 study, the
Autor:
Guiping Chen, Bo O. Chen, Hua Wang, Yipeng Xu, Yang Zhao, Shaoxing Zhu, Fangyin Li, Zongping Wang
Publikováno v:
Oncology Letters
Penile verrucous carcinoma is an extremely rare disease that, at present, has not been well characterized. The etiology, diagnosis and treatment of this carcinoma remain poorly understood, particularly in the Chinese population. The aim of the presen